In critically ill patients admitted to the intensive care unit, the presence of neutropenia is associated with an increased risk of acute respiratory distress syndrome.
In patients with pulmonary hypertension undergoing rehabilitation, greater inclusion of outcome measures is needed to facilitate accurate assessment of the wider effect this intervention.
So far, the therapies scheduled to be part of the trial are risankizumab, an interleukin-23 antagonist, and lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
Investigators conducted a single-center study to evaluate the anti-SARS-CoV-2 antibodies at baseline and 60 days in health care personnel, who are at particular risk if antibodies level decline.
Point-of-care testing is associated with large reductions in the time to results for patients presenting with suspected COVID-19.
Pulmonary hypertension is associated with higher in-hospital mortality, morbidity, length of stay, and health care utilization in patients admitted to the hospital with an acute exacerbation of COPD.
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Lung involvement during hospitalization for systemic lupus erythematosus may be associated with greater inpatient mortality.